PARIS (dpa-AFX) - Applied Genetic Technologies Corp. (AGTC) has a couple of
catalysts coming its way this year.
A phase I/II clinical trial of the company's XLRS product candidate for the
treatment of X-Linked Retinoschisis has enrolled a...
Applied Genetic Technologies (AGTC) and Bionic Sight are teaming up to develop a new form of optogenetic therapy that can restore vision in patients who have visual deficiencies or are blind as a result of retinal disease. The technology will...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to GENETIC TECHNOLOGIES (GENE):